A unique tool to support or validate your cardiac efficacy data

IPST’s exclusive use of healthy human cardiovascular tissues in a validated, fully compliant context, has provided the pharmaceutical industry with a unique tool for verifying efficacy in functional human tissues devoid of pathologies.

Molecules targeting cardiovascular indications can be tested for efficacy in human tissues very early in preclinical development, through a series of electrophysiological or contraction relaxation measurements.  The scientific and financial advantages associated with the in-vitro use of human tissues are evident: absence of species-specific differences, direct measurement of functional interactions with the intended targets, unequivocal demonstration of efficacy for compounds in early drug development.

In assembling a range of validated assays using human tissues in an in-vitro context, IPST has thought of both scientists and investors. As scientists, we are definitely interested in the fate of the molecules we test and develop, however, we also are well aware of the importance of satisfying investor concerns at various times during the drug development process.  The human cardiac efficacy models have thus far established a splendid historical record as both predictors of cardiac toxicity, and models of efficacy for cardiovascular compounds.

Contact us for more info:
info@ipstherapeutique.com